Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis

Table 1

Basic characteristics of 16 included studies.

Author and Year	Treatment Course (weeks)	Age (T/C)	Number(T/C)	Interventions (T/C)	Outcome Indicators
Chen 2019 [13]	6w	46.34 ± 7.88/45.67 ± 7.91	46/46	Cinobufacin + NX/NX	A1C2C3
Guo 2019 [14]	8w	45.37 ± 7.68/45.54 ± 7.82	60/60	Cinobufacin + pirarubicin/Pirarubicin	A1A2C1C2C3D1D4
Lei 2019 [15]	6w	50.42 ± 3.62/50.46 ± 3.68	29/29	Cinobufacin + DC/DC	A1A2D1D2D5
He 2018 [16]	8w	43.7 ± 1. 9/44.33 ± 2.1	68/68	Cinobufacin + TEC/TEC	A1A2D1
Wang 2018 [17]	6w	Median age 54	35/35	Cinobufacin + DC/DC	A1A2B2D1D2D5
Tian 2017 [18]	9–18w	50.27 ± 6.23/49.57 ± 5.86	31/31	Cinobufacin + basic scheme containing capecitabine/Basic scheme containing capecitabine	A1A2C1C2C3
Ke 2017 [19]	12w	38. 3 ± 8. 9/39. 5 ± 8.8	20/21	Cinobufacin + CAF/CAF	A1A2B1B2D1D3D4
Deng 2017 [20]	6w	50.27 ± 6.23/49.57 ± 5.86	31/31	Cinobufacin + basic scheme containing capecitabine/Basic scheme containing capecitabine	A1A2C1C2C3
Yang 2016 [21]	8w	34.58 ± 14.44	40/41	Cinobufacin + TAC/TAC	A1A2B1D1D2D3
Dong 2011 [22]	6w	Average age 53	20/22	Cinobufacin + DC/DC	A1A2B1B2D1D2D5
Pan 2011 [23]	6w	Average age 56	80/80	Cinobufacin + CAF/CAF	A1A2D1D2D4
Song 2002 [24]	4w	Median age 54	26/21	Cinobufacin + CAF/CAF	A1A2D1D2D3
Sun 2019 [25]	6w	41.85 ± 2.25/43.56 ± 3.02	56/56	Cinobufacin + TEC/TEC	A1A2B1D1D2D3
Li 2019 [26]	9w	49.34 ± 7.34/48.36 ± 8.52	30/30	Cinobufacin + Basic scheme containing capecitabine/Basic scheme containing capecitabine	A1A2C1C2C3D1
Mai 2019 [27]	6w	44.10 ± 2.92/43.50 ± 3.71	25/25	Cinobufacin + docetaxel sequential CEF/Docetaxel sequential CEF	A1A2D1D3
Li 2018 [28]	—	47.5 ± 11.2/48.5 ± 10.8	69/69	Cinobufacin + pemetrexed combined with DDP/Pemetrexed combined with DDP	A1A2C2C3D1D3D4

Notes: T/C: treatment group/control group. A1(ORR); A2(CBR); B1(KPS score); B2(pain relief rate); C1(CA125); C2(CA153); C3(CEA); D1(gastrointestinal reaction); D2(myelosuppression); D3(liver and kidney damage); D4(alopecia); D5(peripheral neurotoxicity). TAC: docetaxel + pirarubicin + cyclophosphamide; TEC: docetaxel + epirubicin + cyclophosphamide; NX: capecitabine + vinorelbine; CAF: cyclophosphamide + pirarubicin + 5-FU; DC: docetaxel + capecitabine; CEF: cyclophosphamide + epirubicin + 5-FU.